SHANGHAI, Dec. 22 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the highest rates of revenue growth during the preceding three years.
(Logo: http://www.prnasia.com/sa/2009/04/01/200904011147.jpg )
"We are pleased and honored to receive this award again," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "It speaks to the soundness of our long-term business model and the effort, talent, and customer focus of our scientists. At WuXi PharmaTech, we continue to expand our pharmaceutical R&D service capabilities and capacity to best serve our customers and to sustain long-term revenue growth."
For more information, please contact:
WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email: ir@wuxiapptec.com
Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email: pr@wuxiapptec.com
